NCT05214482 2026-03-03
A Study of AK112 in Advanced Malignant Tumors
Akeso
Phase 1/2 Completed
Clinical Trials
251 trialsNCT04798664 2026-02-25
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT01013649 2026-02-23
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT05731947 2026-01-29
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT07304388 2025-12-30
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Sun Yat-sen University
Phase 2 Completed
NCT02314182 2025-12-19
GRECCAR8
Hospices Civils de Lyon
Phase 3 Completed
NCT04699539 2025-12-10
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
Changhai Hospital
Phase NA Completed
NCT05440916 2025-12-02
PRIMM
University Medical Centre Maribor
Phase 2 Completed
NCT02918955 2025-11-20
UPFRONT-NECK
Insel Gruppe AG, University Hospital Bern
Phase 3 Completed
NCT04603586 2025-10-20
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
Changhai Hospital
Phase NA Completed
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05775796 2025-10-01
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
Fudan University
Phase 2 Completed
NCT06341998 2025-09-19
SCRRYST
Shandong First Medical University
Phase 2/3 Completed
NCT07152938 2025-09-15
AVR-CHEMO
Arab American University (Palestine)
Phase NA Completed
NCT03581786 2025-09-02
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT06186700 2025-07-28
Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer
Mansoura University
Phase 2 Completed
NCT06048913 2025-07-04
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT06533722 2025-06-10
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04082364 2025-06-08
MAHOGANY
MacroGenics
Phase 2/3 Completed
NCT02649829 2025-04-29
MESODEC
University Hospital, Antwerp
Phase 1/2 Completed
NCT03632135 2025-04-15
CSCRGBM
Cordgenics, LLC
Phase 3 Completed
NCT03257267 2025-04-08
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT03353831 2025-04-06
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT03409614 2025-03-13
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT02278887 2025-03-10
TIL
The Netherlands Cancer Institute
Phase 3 Completed
NCT04997382 2025-02-25
CLASSIC5
Hunan Province Tumor Hospital
Phase 2 Completed
NCT04091867 2025-02-24
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
Phase 1 Completed
NCT01957735 2025-02-19
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
BPGbio
Phase 1 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02151981 2025-01-07
AURA3
AstraZeneca
Phase 3 Completed
NCT04449861 2024-11-27
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
AstraZeneca
Phase 3 Completed
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT03227328 2024-11-07
KENDO
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT03985046 2024-11-07
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Phase 2 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT03873883 2024-09-19
IO-001
iTeos Therapeutics
Phase 1 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT05865548 2024-08-13
Addition of Aspirin to Standard of Care in Oral Cancer
Banaras Hindu University
Phase 2/3 Completed
NCT03539406 2024-08-09
INTRO
Radboud University Medical Center
Phase 1 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT04902885 2024-07-10
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01827553 2024-04-11
CONKO-007
University of Erlangen-Nürnberg Medical School
Phase 3 Completed
NCT00837265 2024-04-03
NEUGR-002
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2/3 Completed
NCT00596154 2024-04-01
PCNSL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed